NCT06812988进行中（未招募）2 期
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of Brivekimig, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- Sanofi
- 入组人数
- 84
- 试验地点
- 37
- 主要终点
- Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentration
研究概览
简要总结
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study.
The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy.
The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo).
The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.
详细描述
The total study duration will be up to 83 weeks including Screening and Safety follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 35 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 to 35 y.o. inclusive, at the time of signing the informed consent in order to be enrolled in Part A. Participant must be 12 to 21 y.o. inclusive, at the time of signing the informed consent in order to be enrolled in Part B.
- •Participants who meet the criteria of T1D according to American Diabetes Association (ADA 2024).
- •Initiated exogenous insulin replacement therapy not longer than 90 days prior to Screening visit at which random C-peptide will be assessed.
- •Receiving insulin hormone replacement therapy:
- •Participants must be positive for at least 1 of the following T1D autoantibodies confirmed by medical history and/or obtained at study Screening:
- •Glutamic acid decarboxylase (GAD-65)
- •Insulinoma Antigen-2 (IA-2)
- •Zinc-transporter 8 (ZnT8) or
- •Insulin (if obtained not later than 10 days after exogenous insulin therapy initiation)
- •Have random C-peptide levels ≥0.2 nmol/L determined at Screening.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Serious systemic viral, bacterial or fungal infection (eg, pneumonia, pyelonephritis), infection requiring hospitalization or intravenous (IV) antibiotics or significant chronic viral (including history of recurrent or active herpes zoster, acute or active cytomegalovirus [CMV], Epstein-Barr Virus [EBV] as determined at Screening), bacterial, or fungal infection (eg, osteomyelitis) 30 days before and during Screening.
- •History of invasive opportunistic infections, such as, but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, and aspergillosis, regardless of resolution.
- •Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing.
- •Evidence of any clinically significant, severe or unstable, acute or, chronically progressive, uncontrolled infection, medical or surgical condition (eg, but not limited to, cerebral, cardiac, pulmonary, renal, hepatic, gastrointestinal, neurologic, or any known immune deficiency), or any condition that may affect participant safety in the judgment of the Investigator (including vaccinations which are not updated based on local regulation).
- •History of a systemic hypersensitivity reaction or significant allergies, other than localized injection site reaction, to any humanized mAb. Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
- •History of moderate to severe congestive heart failure (New York Health Association [NYHA] Class III or IV), or recent cerebrovascular accident, or any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol.
- •History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.
- •Has other autoimmune or inflammatory conditions
- •Diabetes of forms other than autoimmune T1D that include but are not limited to genetic forms of diabetes, maturity-onset diabetes of the young (MODY), latent autoimmune diabetes of the adult (LADA), secondary to medications or surgery, type 2 diabetes by judgment of the investigator.
- •History of malignancy or lymphoproliferative disease other than adequately treated localized carcinoma in situ of the cervix or nonmetastatic squamous cell carcinoma, or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured or any family history in two or more relatives (immediate family) of same cancer (ie, rare cancers, those manifesting at a young age in a parent or sibling, certain genetic-based inheritable cancers).
- •Systemic corticosteroids (duration >7 days), adrenocorticotropic hormone 1 month prior to Screening.
- •Any IV, intramuscular (IM) or SC administered biologic treatments (mono- or polyclonal antibodies affecting function of immune system), <3 months or <5 half-lives (whichever is longer), prior to randomization.
- •Any live (attenuated or viral-vector) vaccine (including but not limited to varicella zoster, oral polio, nasal influenza, rabies) within 3 months prior to randomization or is scheduled in expected period of study (78 weeks after randomization) if this vaccination cannot be safely postponed.
- •Any non-live (inactivated, mRNA, recombinant, conjugate, toxoid) vaccine administered less than 14 days prior to randomization.
- •Any immunosuppressive therapy within 12 weeks prior to randomization and through 78 weeks after randomization
- •Course of Thymoglobulin®, teplizumab or other immunomodulatory treatments at any time
- •Any drugs that may be used for treatment of T1D and type 2 diabetes other than insulin including but not limited to metformin, glucagon-like peptide 1 (GLP-1) agonists, sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor, and verapamil within 2 weeks prior to Screening.
- •Abnormal laboratory test(s) at Screening
- •Participants who have impaired renal function with estimated glomerular filtration rate (eGFR) (using the Modification of Diet in Renal Disease [MDRD] formula) <60 mL/min/1.73 m2, or using the bedside Schwartz equation in the participants under the age of 18 y.o.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive subcutaneous injection of matching placebo.
干预措施: Placebo (Drug)
Brivekimig
Experimental
Participants will receive subcutaneous injection of brivekimig.
干预措施: Brivekimig (Drug)
结局指标
主要结局
Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentration
时间窗: From Baseline to Week 26
Mixed meal tolerance test MMTT stimulated C-peptide concentration is to be calculated from area under the concentration-time curve (AUC)
次要结局
- Change from baseline to Week 52 in mean 2-hour MMTT stimulated Cpeptide concentration(From Baseline to Week 52)
- Participant remaining C-peptide positive at Week 26 and Week 52(Week 26 and Week 52)
- Time in range (TIR) (70-180 mg/dL) at Week 26 and Week 52(Week 26 and Week 52)
- Change from baseline to Week 26 and Week 52 in insulin dose(From Baseline to Week 26 and Week 52)
- Change from baseline to Week 26 and Week 52 in glycated hemoglobin A1c (HbA1c) level(From Baseline to Week 26 and Week 52)
- Participant having HbA1c ≤6.5% and ≤0.25 IU/kg/day of exogenous insulin required at Week 26 and Week 52(Week 26 and Week 52)
- Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and TEAEs leading to treatment discontinuation(Up to End of Study (approx. 83 Weeks))
- Incidence (yes/no) of hypoglycemic events (level 2 or 3 according to American Diabetes Association)(Up to End of Study (approx. 83 Weeks))
- Incidence (yes/no) of hyperglycemic episodes (level 2 according to American Diabetes Association)(Up to End of Study (approx. 83 Weeks))
- Incidence (yes/no) of diabetic ketoacidosis (DKA) events(Up to End of Study (approx. 83 Weeks))
- Incidence (yes/no) of clinically significant changes in vital signs, electrocardiogram (ECG), and/or laboratory evaluation(Up to End of Study (approx. 83 Weeks))
- Incidence of anti-drug antibodies (ADAs) over time(Up to End of Study (approx. 83 Weeks))
- Change from baseline to Week 26 and Week 52 in Problem Areas in Diabetes (PAID) total score (all participants)(From Baseline to Week 26 and Week 52)
- Change from baseline to Week 26 and Week 52 in PAID immediate and theoretical domain scores (caregivers of all participants 12 to 17 y.o.)(From Baseline to Week 26 and Week 52)
- Brivekimig serum concentrations over time(Up to End of Study (approx. 83 Weeks))
研究者
研究点 (37)
Loading locations...
相似试验
已完成
2 期
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SARSeasonal Allergic RhinitisHayfeverNCT00854360Teva Branded Pharmaceutical Products R&D, Inc.487
已完成
2 期
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABAAsthmaNCT06020014AstraZeneca339
已完成
2 期
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)Essential TremorNCT05122650Jazz Pharmaceuticals420
已完成
2 期
Study of CA-008 (Vocacapsaicin) in Total Knee ArthroplastyPostsurgical PainNCT03731364Concentric Analgesics55
已完成
2 期
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor NeuropathyMultifocal Motor NeuropathyNCT05225675argenx54